4//SEC Filing
Lloyd George W. 4
Accession 0001802768-23-000032
CIK 0001802768other
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 7:35 PM ET
Size
17.0 KB
Accession
0001802768-23-000032
Insider Transaction Report
Form 4
Lloyd George W.
EVP, Investments & CLO
Transactions
- Conversion
Class A Ordinary Shares
2023-11-13+50,000→ 80,000 total(indirect: By LLC) - Conversion
Class A Ordinary Shares
2023-11-13+100,000→ 220,000 total(indirect: By LLC) - Conversion
LP interests in RPI US Partners 2019, LP
2023-11-13−5,000→ 245,299 total(indirect: By LLC)Exercise: $0.00→ Class A Ordinary Shares (50,000 underlying) - Conversion
LP interests in RPI US Partners 2019, LP
2023-11-13−10,000→ 162,680 total(indirect: By LLC)Exercise: $0.00→ Class A Ordinary Shares (100,000 underlying)
Holdings
- 273,960(indirect: By IRA)
Class A Ordinary Shares
- 3,000
Class A Ordinary Shares
- 4,011(indirect: By Spouse)
Class A Ordinary Shares
- 8,173(indirect: By LLC)
LP interests in RPI US Partners 2019, LP
Exercise: $0.00→ Class A Ordinary Shares (81,730 underlying) - 495,860(indirect: By LLC)
Class A Ordinary Shares
Footnotes (3)
- [F1]These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.
- [F2]The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.
- [F3]Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Documents
Issuer
Royalty Pharma plc
CIK 0001802768
Entity typeother
Related Parties
1- filerCIK 0001814899
Filing Metadata
- Form type
- 4
- Filed
- Nov 13, 7:00 PM ET
- Accepted
- Nov 14, 7:35 PM ET
- Size
- 17.0 KB